Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey W Chisholm

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Lipid Research|November 12, 2005
Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changesDavid Masson, Jean-Paul Pais de Barros, Zoulika Zak, et al.
Journal of Lipid Research|July 19, 2005
HDLs in apoA-I transgenic Abca1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidneyJi-Young Lee, Jenelle M Timmins, Anny Mulya, et al.
Journal of Biomolecular Screening|July 20, 2012
Lipid-sensing high-throughput ApoA-I assaysAnita Niedziela-Majka, Latesh Lad, Jeffrey W Chisholm, et al.
The Journal of Clinical Investigation|July 12, 2005
Liver X receptors alpha and beta regulate renin expression in vivoFulvio Morello, Rudolf A de Boer, Knut R Steffensen, et al.
Bioorganic & Medicinal Chemistry Letters|July 7, 2009
Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitorsDmitry O Koltun, Timur M Zilbershtein, Vasily A Migulin, et al.
Bioorganic & Medicinal Chemistry Letters|March 3, 2009
Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitorsDmitry O Koltun, Eric Q Parkhill, Natalya I Vasilevich, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2009
Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitorsDmitry O Koltun, Natalya I Vasilevich, Eric Q Parkhill, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Lipid Research|November 12, 2005
Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changesDavid Masson, Jean-Paul Pais de Barros, Zoulika Zak, et al.
Journal of Lipid Research|July 19, 2005
HDLs in apoA-I transgenic Abca1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidneyJi-Young Lee, Jenelle M Timmins, Anny Mulya, et al.
Journal of Biomolecular Screening|July 20, 2012
Lipid-sensing high-throughput ApoA-I assaysAnita Niedziela-Majka, Latesh Lad, Jeffrey W Chisholm, et al.
The Journal of Clinical Investigation|July 12, 2005
Liver X receptors alpha and beta regulate renin expression in vivoFulvio Morello, Rudolf A de Boer, Knut R Steffensen, et al.
Bioorganic & Medicinal Chemistry Letters|July 7, 2009
Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitorsDmitry O Koltun, Timur M Zilbershtein, Vasily A Migulin, et al.
Bioorganic & Medicinal Chemistry Letters|March 3, 2009
Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitorsDmitry O Koltun, Eric Q Parkhill, Natalya I Vasilevich, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2009
Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitorsDmitry O Koltun, Natalya I Vasilevich, Eric Q Parkhill, et al.
Pageof 2